Demographical risk factors of adverse events following immunisation of CoronaVac in Jambi, Indonesia
DOI:
https://doi.org/10.53638/phpma.2023.v11.i1.p05Keywords:
COVID-19 vaccine, adverse event following immunization, vaccine reaction, IndonesiaAbstract
Background and purpose: Slow uptake of COVID-19 vaccination might be associated with the adverse events after vaccination. This study aims to evaluate the association between demographical factors and COVID-19 vaccine adverse events in Jambi, Indonesia
Methods: We conducted a cross-sectional study with a total population sampling. Data were collected with a structured questionnaire. We included adults vaccinated for the first dose with CoronaVac in Putri Ayu Public Health Center between March 15th and June 3rd, 2021, accounted for 522 persons. Statistical analysis was done using IBM SPSS 26.0. Multivariate logistic regression analysis was used to analyze the predictive models.
Results: This Out of 522 respondents included, immune reactions (34.1%) were the most common adverse effects reported by the respondents. Multivariate analysis showed that respondents with no family members or friends exposed to COVID-19 are less likely to experience puncture site reaction with an OR of 0.28 (95%CI: 0.09-0.92; p=0.036). Those with no history of mental disorders were also less likely to experience the adverse event with an OR of 0.12 (95%CI: 0.024-0.62; p=0.011). As for other reactions, those in the 26-35 years old category are more likely to experience other adverse event reactions with an OR of 11.62 (95%CI: 1.5-89.92; p=0.019).
Conclusion: Based Younger respondents tend to experience more other reaction of COVID-19 vaccine adverse events than the older groups. We also found that those with no family or friends who contracted COVID-19 and no history of mental disorders are less likely to experience puncture site reaction adverse events.
References
Mercier G, Arquizan C, Roubille F. Understanding the effects of COVID-19 on health care and systems. Lancet Public Heal. 2020;5(10):e524.
Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics (Basel, Switzerland). 2021;10(3):1–10.
Chang AY, Cullen MR, Harrington RA, Barry M. The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. J Intern Med. 2021;289(4):450–62.
Bojdani E, Rajagopalan A, Chen A, Gearin P, Olcott W, Shankar V, et al. COVID-19 Pandemic: Impact on psychiatric care in the United States. Psychiatry Res. 2020;289:113069.
Chen LH, Petersen E, Blumberg L, Piyaphanee W, Steffen R. COVID-19 health passes: current status and prospects for a global approach. J Travel Med. 2021;28(7).
Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. Coronavirus Pandemic (COVID-19). Our World Data. 2020;5(7):947–53.
United Nations Children's Fund. Indonesia COVID-19 Response Situation Report 2021 [cited 2022 Nov 7]. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/UNICEF%20Indonesia%20COVID-19%20Situation%20Report%20-%20April%20to%20June%202021.pdf
COVIDVax. Live COVID-19 Vaccination Tracker: Indonesia 2022 covidvax.live - Indonesia . [cited 2022 Nov 7]. Available from: https://covidvax.live/location/idn
Waters EA, Weinstein ND, Colditz GA, Emmons KM. Aversion to side effects in preventive medical treatment decisions. Br J Health Psychol. 2007;12(3):383–401.
Possible Side Effects After Getting a COVID-19 Vaccine | CDC . [cited 2022 Nov 7]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html
Food and Health Bureau (FHB). Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021 [cited 2022 Nov 7]. Available from: https://www.fhb.gov.hk/download/our_work/health/201200/e_evaluation_report_CoronaVac.pdf
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1–18.
Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the bnt162b2 mrna vaccine in a local vaccination center in germany. Vaccines. 2021;9(8):1–10.
Heriyanto RS, Kurniawan A, Wijovi F, Halim DA, Jodhinata C, Marcella E, et al. The role of COVID‐19 survivor status and gender towards neutralising antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia. Int J Infect Dis. 2021;113:336–8.
Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunisation database, and the role of cognitive biases. BMC Public Health. 2021;21(1):1–13.
Yanto TA, Octavius GS, Heriyanto RS, Ienawi C, Nisa H, Pasai HE. Psychological factors affecting COVID-19 vaccine acceptance in Indonesia. Egypt J Neurol Psychiatry Neurosurg. 2021;57(1):177.
Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:2465–2475.
Muhyiddin M, Nugroho H. A Year of COVID-19: A Long Road to Recovery and Acceleration of Indonesia's Development. J Perenc Pembang Indones J Dev Plan. 2021;5(1):1–19.
Indonesian Society of Internal Medicine. Rekomendasi PAPDI tentang Pemberian Vaksinasi COVID-19 pada Pasien dengan Penyakit Penyerta/Komorbid (Revisi 18 Maret 2021) [Recommendations of The Indonesian Internal Medicine Association regarding COVID-19 vaccination for patients with comorbidities (18 March 2021 revision)]. [cited 2022 Nov 8]. Available from: https://www.papdi.or.id/berita/info-papdi/1024-rekomendasi-papdi-tentang-pemberian-vaksinasi-covid-19-pada-pasien-dengan-penyakit-penyerta-komorbid-revisi-18-maret-2021
Indonesian Society of Obstetrics and Gynecology. Rekomendadi POGI Terkait Melonjaknya Kasus Ibu Hamil dengan COVID-19 dan Perlindungan Terhadap Tenaga Kesehatan [Recommendations of the Indonesian Obstetrics and Gynecogy Association regarding the increase number of pregnant women with COVID-19 and the protection of health care workers]. Vol. 4247608. 2021. p. 5.
Indonesian Pediatric Society. Rekomendasi Ikatan Dokter Anak Indonesia tentang Pemberian Vaksin COVID-19 (Coronavac®) pada anak usia 6–11 Tahun (Pemutakhiran 16 Desember 2021) [Recommendations of the Indonesian Pediatricians Association regarding COVID-19 vaccination (Coronavac®) among children aged 6-11 year old (16 December 2021 version]. 2021;(5):1–3. Available from: www.idai.or.id
The Indonesia Ministry of Health. COVID-19 Vaccine Acceptance Survey in Indonesia. J Mater Process Technol. 2020;1(1):1–8.
Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043–51.
Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654–7.
Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, et al. Prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12).
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939–49.
Riad A, Pokorná A, Klugarová J, Antalová N, Kantorová L, Koščík M, et al. Side effects of mrna-based COVID-19 vaccines among young adults (18–30 years old): An independent post-marketing study. Pharmaceuticals. 2021;14(10).
Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19 Vaccines Programs: adverse events following immunisation (AEFI) among medical Clerkship Students in Jember, Indonesia. BMC Pharmacol Toxicol. 2021;22(1).
Statistics Bureau. Population Based on Age Group and Gender 2019. [cited 2022 Nov 8]. Available from: https://www.bps.go.id/indikator/indikator/view_data_pub/0000/api_pub/YW40a21pdTU1cnJxOGt6dm43ZEdoZz09/da_03/1
Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events | CDC [Internet]. [cited 2022 Nov 8]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html
Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120(4):435.
Geers AL, Clemens KS, Faasse K, Colagiuri B, Webster R, Vase L, et al. Psychosocial Factors Predict COVID-19 Vaccine Side Effects. Psychother Psychosom. 2021;1–3.
Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, et al. Routine surveillance of adverse events following immunisation as an important tool to monitor vaccine safety: The two-years' experience of the Liguria Region, Italy. Hum Vaccin Immunother. 2015;11(1):91.
Sedgwick P. Non-response bias versus response bias. BMJ. 2014;348.
Wright KB. Researching internet-based populations: Advantages and disadvantages of online survey research, online questionnaire authoring software packages, and web survey services. J Comput Commun. 2005;10(3).
Andrade C. The Limitations of Online Surveys. Indian J Psychol Med. 2020;42(6):575–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rivaldo Heriyanto, Theo Audi Yanto, Gilbert Sterling Octavius, Haviza Nisa, Catherine Ienawi, Emildan Pasai
This work is licensed under a Creative Commons Attribution 4.0 International License.
**Creative Commons Attribution 4.0 International License (CC BY 4.0)**
*Welcome to the world of open collaboration and shared creativity! The Creative Commons Attribution 4.0 International License (CC BY 4.0) empowers creators to share their work with the world while maintaining certain rights.*
**Key Points:**
1. **Freedom to Share:** CC BY 4.0 allows creators to share their work globally, granting others the freedom to use, remix, and build upon it.
2. **Attribution Requirement:** Users can use the work for any purpose, even commercially, as long as they provide appropriate credit to the original creator.
3. **Flexibility:** Applicable to various content types—text, images, music, videos—the license fosters a diverse range of creations.
**Common Use Cases:**
- **Education:** Widely used for educational materials, promoting open learning environments.
- **Research:** Applied to scholarly articles, accelerating the dissemination of knowledge.
**How to Use:**
1. **Share:** Share your work with the world, marking it with the CC BY 4.0 license.
2. **Attribution:** Users, when utilizing the work, must provide proper attribution to honor the original creator.
**Conclusion:**
CC BY 4.0 contributes to a more open and collaborative digital landscape. Join the movement of shared knowledge and creativity!
*For full license details, visit [Creative Commons](https://creativecommons.org/licenses/by/4.0/).*
